Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples

Clinical Infectious Diseases

Volumn 62, Issue 4, 2015, Pages 456-461

  Magaret, Amalia S ^a,b,c   Mujugira, Andrew ^a,b   Hughes, James P ^a,b,c   Lingappa, Jairam ^a,b   Bukusi, Elizabeth A ^d,s   Debruyn, Guy ^e   Delany Moretlwe, Sinead ^f   Fife, Kenneth H ^g,p   Gray, Glenda E ^h   Kapiga, Saidi ^i,t   Karita, Etienne ^j,r   Mugo, Nelly R ^d   Rees, Helen ^f   Ronald, Allan ^k,l   Vwalika, Bellington ^j,m,r   Were, Edwin ^n,p   Celum, Connie ^a,b   Wald, Anna ^a,b,c   Baeten, Jared M ^b   Campbell, Mary ^b   Corey, Lawrence ^b   Coombs, Robert W ^b   McElrath, M Juliana ^b   Morrow, Rhoda ^b   Mullins, James I ^b   Coetzee, David ^o   Essex, Max ^q   Makhema, Joseph ^q   Katabira, Elly ^l   Allen, Susan ^r   Kayitenkore, Kayitesi ^r   Cohen, Craig ^s   Kanweka, William ^r   Manongi, Rachel ^t   Farquhar, Carey ^b   John Stewart, Grace ^b   Kiarie, James ^b   Inambao, Mubiana ^r   De Bruyn, Guy ^h   McIntyre, James ^h   Mugo, Nelly Rwamba ^b   more..

^a Department of Laboratory Medicine ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e SANOFI PASTEUR   (France)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Rwanda Zambia HIV 1 Research Group   (Zambia)

^k UNIVERSITY OF MANITOBA   (Canada)

^l MAKERERE UNIVERSITY   (Uganda)

^m UNIVERSITY OF ZAMBIA   (Zambia)

ⁿ MOI UNIVERSITY   (Kenya)

^o UNIVERSITY OF CAPE TOWN   (South Africa)

^p INDIANA UNIVERSITY   (United States)

^q BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^r EMORY UNIVERSITY   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t HARVARD UNIVERSITY   (United States)

more..

Author keywords

condom; efficacy; HIV; HSV 2; transmission

Indexed keywords

ADULT; AFRICAN; ARTICLE; CONDOM USE; FEMALE; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SEXUAL TRANSMISSION; UNPROTECTED SEX; VIRUS TRANSMISSION; CLINICAL TRIAL; COMPLICATION; CONDOM; CONTROLLED STUDY; DISEASE TRANSMISSION; FAMILY SIZE; HERPES GENITALIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSMISSION;

CONDOMS; DISEASE TRANSMISSION, INFECTIOUS; FAMILY CHARACTERISTICS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; INFECTION CONTROL; MALE; RISK ASSESSMENT;

EID: 84983113151     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ908     Document Type: Article

References (26)

1. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999-2010. J Infect Dis 2014; 209:325-33.
2. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008; 86:805-12, A.
3. Corey L,Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
4. Kim HN,Wald A, Harris J, Almekinder J, Heitman C, Corey L. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis 2008; 35:124-8.
5. Venkatesh KK, van der Straten A, Cheng H, et al. The relative contribution of viral and bacterial sexually transmitted infections on HIV acquisition in southern African women in the Methods for Improving Reproductive Health in Africa study. Int J STD AIDS 2011; 22:218-24.
6. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43.
7. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011; 121:4600-9.
8. FDA. Class II Special Controls Guidance Document: Labeling for Natural Rubber Latex Condoms. Guidance Documents (Medical Devices and Radiation-Emitting Products) Vol. 21CFR884.5300, 1998.
9. Gallo MF, Warner L, Macaluso M, et al. Risk factors for incident herpes simplex type 2 virus infection among women attending a sexually transmitted disease clinic. Sex Transm Dis 2008; 35:679-85.
10. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169: 1233-40.
11. Moss NJ, Harper CC, Ahrens K, et al. Predictors of incident herpes simplex virus type 2 infections in young women at risk for unintended pregnancy in San Francisco. BMC Infec Dis 2007; 7:113.
12. Stanaway JD, Wald A, Martin ET, Gottlieb SL, Magaret AS. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis 2012; 39:388-93.
13. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-6.
14. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
15. Mujugira A, Magaret AS, Celum C, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 2013; 208:1366-74.
16. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662-7.
17. Jewell NP, Shiboski SC. Statistical analysis of HIV infectivity based on partner studies. Biometrics 1990; 46:1133-50.
18. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205:358-65.
19. Campbell MS, Mullins JI, Hughes JP, et al. Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One 2011; 6:e16986.
20. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-22.
21. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 2011; 8:e1000416.
22. Weinfurt KP, Lin L, Dombeck CB, et al. Accuracy of 30-day recall for components of sexual function and the moderating effects of gender and mood. J Sex Med 2014; 11:678-96.
23. Ashley RL, Eagleton M, Pfeiffer N. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J Clin Microbiol 1999; 37:1632-3.
24. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken, NJ: Wiley, 2002.
25. Meier AS, Richardson BA, Hughes JP. Discrete proportional hazards models for mismeasured outcomes. Biometrics 2003; 59:947-54.
26. Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 2004; 11(suppl 3):130A-7.